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Abstract
Inflammation critically contributes to cancer metastasis, in which myeloid-derived suppressor 
cells (MDSCs) are an important participant. Although MDSCs are known to suppress immune 
surveillance, their roles in directly stimulating cancer cell proliferation and metastasis currently 
remain unclear. Lysosomal acid lipase (LAL) deficiency causes systemic expansion and 
infiltration of MDSCs in multiple organs and subsequent inflammation. In the LAL-deficient 
(lal−/−) mouse model, melanoma metastasized massively in allogeneic lal−/− mice, which was 
suppressed in allogeneic lal+/+ mice due to immune rejection. Here we report for the first time that 
MDSCs from lal−/− mice directly stimulated B16 melanoma cell in vitro proliferation, and in vivo 
growth and metastasis. Cytokines i.e., IL-1β and TNFα from MDSCs are required for B16 
melanoma cell proliferation in vitro. Myeloid-specific expression of human LAL (hLAL) in lal−/− 
mice rescues these malignant phenotypes in vitro and in vivo. The tumor-promoting function of 
lal−/− MDSCs is mediated, at least in part, through over-activation of the mammalian target of 
rapamycin (mTOR) pathway. Knockdown of mTOR, Raptor or Rictor in lal−/− MDSCs 
suppressed their stimulation on proliferation of cancer cells, including B16 melanoma, LLC and 
Tramp-C2 cancer cells. Our results indicate that LAL plays a critical role in regulating MDSCs 
ability to directly stimulate cancer cell proliferation, and overcome immune rejection of cancer 
metastasis in allogeneic mice through modulation of the mTOR pathway, which provides a 
mechanistic basis for targeting MDSCs to reduce the risk of cancer metastasis. Therefore, MDSCs 
possess dual functions to facilitate cancer metastasis: suppress immune surveillance, and stimulate 
cancer cell proliferation and growth.
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Introduction
Inflammation plays crucial roles at all stages of tumor development, from tumor initiation to 
metastatic progression 1. Metastasis, the leading cause of cancer-associated mortality, 
requires close collaboration between cancer cells and inflammatory cells 1. Lysosomal acid 
lipase (LAL) hydrolyzes cholesteryl esters and triglycerides in the lysosome of cells to 
generate free fatty acids and cholesterol. Genetic ablation of the lal gene in mice has 
resulted in a systemic increase of myeloid lineage cells, causing severe inflammation in 
multiple organs 2, 3. We have previously reported spontaneous lung adenocarcinoma in 
transgenic mice with myeloid-specific overexpression of matrix metalloproteinase 12 
(MMP12) 4, or apoptosis inhibitor 6 (Api6/AIM/Spα) 5, or dominant negative peroxisome 
proliferators-activated receptor-γ (PPARγ) 6, all of which are downstream target or effector 
genes of LAL.
The neutral lipid metabolic pathway controlled by LAL plays a critical role in the 
development and homeostasis of myeloid-derived suppressor cells (MDSCs), and LAL 
deficiency led to the infiltration and accumulation of MDSCs in various organs of the 
mice 2, 3, 7. LAL-deficient (lal−/−) MDSCs arise from dysregulated production of progenitor 
cells in the bone marrow, and have strong suppressive function on T cells 2, 3, 7. MDSCs, 
characterized by the co-expression of myeloid-cell lineage differentiation antigen Gr-1 and 
CD11b in mice, are a heterogeneous population of immature myeloid cells at different 
stages of differentiation 8. In lal−/− mice, almost all Gr-1+ cells are positive for CD11b 5. 
Most lal−/− MDSCs stained double positive for Ly6G and Ly6C (collectively called Gr-1) 5. 
Numerous studies have shown that an immunosuppressive state of MDSCs favors primary 
tumor development 9–15, but whether there is a direct stimulation of MDSCs on cancer cell 
proliferation and growth has not been confirmed. Therefore, the lal−/− animal model is a 
perfect system to address this issue. In humans, altered mononuclear phagocyte 
differentiation (increased CD14+CD16+ and CD14+CD33+ cells, subsets of human MDSCs) 
has been reported with heterozygote carriers of LAL mutations 16. Patient with mutations in 
the LAL gene has been reported to be associated with carcinogenesis 17.
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that 
regulates cell growth, proliferation, migration, survival, protein synthesis, and transcription 
in response to growth factors and mitogens 18. mTOR is the catalytic subunit of two 
distinctive complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). 
Unique accessory proteins, regulatory-associated protein of mTOR (RAPTOR), and 
rapamycin-insensitive companion of mTOR (RICTOR) define the TORC1 and TORC2 
complexes, respectively 19. Oncogenic activation of the mTOR pathway has been reported 
to induce several processes required for cancer cell growth, survival and proliferation 20. 
However, its role in MDSCs is poorly understood. We have recently demonstrated that the 
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mTOR pathway is over-activated in bone marrow-derived lal−/− MDSCs 21. It is entirely 
unknown whether the activation of the mTOR pathway in lal−/− MDSCs plays a role in 
tumor development and metastasis.
In the present study, we focused on the effects of lal−/− MDSCs on proliferation, growth and 
metastasis of cancer cells, especially B16 melanoma cells. Our study demonstrates for the 
first time that lal−/− MDSCs directly stimulate B16 melanoma cell proliferation, growth and 
metastasis by over-activation of the mTOR pathway in the allogeneic mouse model. These 
findings provide not only a mechanistic insight into the LAL deficiency in facilitating 
metastasis, but also a potential target on MDSCs for anti-tumor therapy.
Results
LAL deficiency stimulated B16 melanoma cell growth and metastasis
To see whether LAL deficiency-induced inflammation influences tumor progression and 
metastasis, the B16 melanoma cell model was used for subcutaneous and intravenous 
injection in allogeneic wild type (lal+/+) and lal−/− FVBN mouse models. To examine 
growth potential in vivo, B16 melanoma cells were injected subcutaneously into mice. Large 
subcutaneous tumors were developed in 10 of 10 lal−/− mice, while only 1 of 10 lal+/+ mice 
developed tumors. In addition, the tumors from lal−/− mice (tumor volume = 1189.8 ± 
554.03mm3) were significantly larger when compared with those developed in lal+/+ mice 
(tumor volume = 48.0 ± 31.23mm3, p<0.0001) at 3 weeks post-tumor cell injection (Figure 
1a and b). Next, B16 melanoma cells were injected into the tail veins of mice to detect 
metastatic potential. Two weeks after injection, more B16 melanoma colonies were 
observed in lal−/− mice at the distal lung and liver organs (Figure 1c). Haematoxylin and 
eosin (H&E) staining revealed more neoplastic melanoma cells in the lungs of lal−/− mice 
than those of lal+/+ mice (Figure 1d). Myeloid cell expansion is a major manifestation in 
lal−/− mice 2, 3. To evaluate the effects of LAL in myeloid lineage cells on B16 melanoma 
cell metastasis, a doxycycline-inducible hLAL myeloid-specific expressing Tg/KO triple 
mouse model was used 3, 7. Statistical analysis displayed that two weeks after intravenous 
injection of B16 melanoma cells, doxycycline-treated Tg/KO triple mice showed reduced 
number of melanoma colonies in the lungs compared with untreated mice (Figure 1e), 
suggesting that hLAL expression in lal−/− myeloid cells partially restored immune rejection 
of B16 melanoma cells in the allogeneic mice model. In tumor growth assessment, B16 
melanoma cells were subcutaneously injected into the flank region of Tg/KO triple mice. 
Figure 1f showed that the volume of tumors from doxycycline-treated Tg/KO triple mice 
was decreased by 50% compared with those developed in untreated mice at 2 weeks post-
injection. Taken together, LAL in myeloid lineage cells plays a critical role in rendering 
immune rejection of cancer cells in the allogeneic mouse model.
LAL deficiency in Ly6G+ cells stimulated B16 melanoma cell proliferation
In lal−/− mice, systemic Ly6G+CD11b+ MDSCs elevation has been observed in multiple 
organs 2, 3, 7. To evaluate the influence of lal−/− Ly6G+CD11b+ MDSCs on proliferation of 
B16 melanoma cells, freshly isolated bone marrow-derived lal+/+ or lal−/− Ly6G+ cells were 
co-cultured with B16 melanoma cells for 72 h. In lal−/− mice, since almost all Ly6G+ cells 
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are positive for CD11b, Ly6G antibody was used for purification of Ly6G+CD11b+ cells 5. 
As shown in Figure 2a, the number of B16 melanoma cells was significantly increased after 
co-culture with lal−/− Ly6G+ cells, suggesting that lal−/− Ly6G+ cells exert a directly 
stimulatory effect on proliferation of B16 melanoma cells in vitro. When Ly6G+ cells from 
doxycycline-treated Tg/KO triple mice were co-cultured with B16 melanoma cells in vitro, 
reduced proliferation of B16 melanoma cells was observed, compared with those of 
untreated Tg/KO triple mice. Since in vitro co-culture conditions are not representative of 
the tumor microenvironment, in vivo co-culture experiment was performed to study the 
effect of lal−/− Ly6G+ cells on B16 melanoma cell growth. Matrigel mixed with lal+/+ or 
lal−/− Ly6G+ cells and B16 melanoma cells were subcutaneously injected into allogeneic 
recipient lal+/+ mice. Ten days later, the plugs mixed with lal−/− Ly6G+ cells and B16 
melanoma cells showed larger size than those mixed with lal+/+ Ly6G+ cells and B16 
melanoma cells. Consistently, H&E staining revealed robust melanoma cell proliferation in 
the plugs containing lal−/− Ly6G+ cells, while Ly6G+ cells from doxycycline-treated Tg/KO 
triple mice decreased B16 melanoma cell growth (Figure 2b). Therefore, lal−/− MDSCs 
possess directly stimulatory activity on cancer cell proliferation.
Activated MDSCs secrete cytokines that contribute to tumor cell invasion, proliferation, and 
survival 22. In lal−/− Ly6G+ cells, mRNA levels of IL-1β and TNFα were up-regulated by a 
Real-time PCR analysis, while IL-6 showed no statistical difference (Figure 2c). To examine 
whether these cytokines secreted by lal−/− Ly6G+ cells facilitate melanoma cell 
proliferation, transwell study was performed with Ly6G+ cells seeding in the upper chamber 
and melanoma cells in the lower chamber. After 72 hours co-culture, the number of B16 
melanoma cells that were co-cultured with lal−/− Ly6G+ cells was significantly increased 
(Figure 2d). When Ly6G+ cells were treated with anti-IL-6, IL-1β, or TNFα antibodies to 
neutralize cytokines, the stimulatory effects on melanoma cell proliferation were 
significantly inhibited in anti-TNFα antibody treated group. Although anti-IL-6 and anti-
IL-1β antibodies showed no statistically significant effect, combination of all three cytokine 
antibodies further blocked the stimulatory effect of melanoma cell proliferation by lal−/− 
Ly6G+ cells (Figure 2d). Therefore, cytokines (especially TNFα) secreted by lal−/− Ly6G+ 
cells are, at least in part, responsible for mediating stimulatory effects on cancer cells.
LAL deficiency in Ly6G+ cells facilitated B16 melanoma cell metastasis
Since lal−/− Ly6G+ cells possess both immune suppressive function on T cells 3 and 
stimulatory function on cancer cells, it is intriguing to investigate if lal−/− Ly6G+ cells 
facilitate B16 melanoma cell metastasis. Two weeks after intravenous co-injection, 
melanoma metastasized more aggressively in allogeneic recipient lal+/+ mice with co-
injection of lal−/− Ly6G+ cells and B16 melanoma cells than those with lal+/+ Ly6G+ cells 
and B16 melanoma cells (Figure 3a and b). H&E staining and immunohistochemical (IHC) 
staining of the lung sections displayed more neoplastic melanoma cells and Ki67 positive 
proliferative cells in the lungs of lal−/− Ly6G+ cell-injected recipient mice than those from 
lal+/+ Ly6G+ cell-injected recipient mice (Figure 3c).
Zhao et al. Page 4
Oncogene. Author manuscript; available in PMC 2015 October 09.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
mTOR inhibition impaired the ability of lal−/− Ly6G+ cells to enhance B16 melanoma cell 
proliferation and growth
We have recently reported that genes involved in the mTOR signaling pathway were altered 
in bone marrow-derived lal−/− Ly6G+ cells by Affymetrix GeneChip microarray 21. This 
was confirmed by Western blot assay, in which mTOR downstream effectors p70S6K and 
S6 were highly phosphorylated in lal−/− Ly6G+ cells (Figure 4a), indicating over-activation 
of the mTOR pathway. To see whether over-activation of the mTOR pathway contributes to 
stimulation of lal−/− Ly6G+ cells on cancer cell proliferation, Ly6G+ cells were transfected 
with mTOR siRNAs. The knockdown efficiency of several mTOR siRNAs in myeloid cells 
was confirmed by the mTOR protein level and its downstream effectors in Western blot 
assay (Supplementary Figure 1). For the in vitro co-culture study, both lal+/+ and lal−/− 
Ly6G+ cells with mTOR knockdown significantly reduced their abilities to stimulate 
proliferation of B16 melanoma cells (Figure 4b). Similar results were observed in in vivo co-
culture Matrigel assay, which showed less neoplastic cells in the plugs with mTOR siRNA 
inhibition in lal−/− Ly6G+ cells (Figure 4c). This was supported by IHC staining, in which 
less Ki67 positive cells were monitored after mTOR knockdown in Ly6G+ cells (Figure 4d). 
In the tumor areas, positive cells for the endothelial marker CD31, the monocyte/
macrophage marker F4/80, or T cell marker CD3 were all decreased following mTOR 
knockdown in Ly6G+ cells, especially knockdown in lal−/− ly6G+ cells, indicating that both 
tumor-associated angiogenesis and inflammatory cell infiltration were impaired (Figure 4d). 
Taken together, these results suggest that over-activation of the mTOR pathway plays a very 
important role in lal−/− Ly6G+ cells to stimulate B16 melanoma cell proliferation and 
growth.
mTOR Inhibition impaired the ability of lal−/− Ly6G+ cells to facilitate B16 melanoma cell 
metastasis
The role of mTOR pathway in lal−/− Ly6G+ cell-facilitated B16 melanoma cell metastasis 
was further examined. lal+/+ or lal−/− Ly6G+ cells after mTOR siRNA transfection were co-
injected with B16 melanoma cells into allogeneic recipient lal+/+ mice intravenously. Two 
weeks later, mice injected with mTOR siRNA-transfected lal−/− Ly6G+ cells developed less 
melanoma metastatic lesions in their lungs (Figure 5a). Sections of the lungs showed less 
neoplastic cells by H&E staining (Figure 5b) and less Ki67 positive cells by IHC staining 
(Figure 5c). These observations suggest that over-activation of the mTOR signaling pathway 
in lal−/− Ly6G+ cells facilitates B16 melanoma cell metastasis.
Raptor and Rictor inhibition impaired the abililty of lal−/− Ly6G+ cells to enhance B16 
melanoma cell proliferation, growth and metastasis
To assess which mTOR complexes (mTORC1 or mTORC2) is involved in lal−/− Ly6G+ 
cells’ stimulatory effects, Ly6G+ cells were transfected with Raptor, Rictor or control 
siRNAs. The decreased protein expression levels of Raptor and Rictor in Ly6G+ cells after 
siRNAs transfections have been confirmed previously 19. For in vitro co-culture study, 
Raptor and Rictor knockdown significantly reduced lal−/− Ly6G+ cell stimulation of 
melanoma cell proliferation (Figure 6a). Similarly, in the in vivo co-culture Matrigel assay, 
less neoplastic cells were detected in the plugs with Raptor and Rictor knockdown in lal−/− 
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Ly6G+ cells (Figure 6b). For in vivo metastasis study, less melanoma metastatic lesions 
developed in the lungs of mice that were co-injected with B16 melanoma cells and Raptor or 
Rictor siRNA-knockdown lal−/− Ly6G+ cells, and H&E staining of lung sections showed 
significantly less neoplastic cells (Figure 6c). Taken together, both mTORC1 and mTORC2 
are involved in lal−/− Ly6G+ cell stimulation on B16 melanoma cell proliferation, growth 
and metastasis.
LAL deficiency in Ly6G+ cells stimulated LLC and Tramp-C2 proliferation and growth, 
which was reversed by mTOR inhibition
To further confirm that lal−/− Ly6G+ cells generally stimulate cancer cell proliferation and 
growth, the above experiments were repeated in two more cancer cell line models, LLC and 
Tramp-C2. In in vitro co-culture study, proliferation of LLC or Tramp-C2 was significantly 
increased after co-cultured with lal−/− Ly6G+ cells (Figure 7a). As shown in Figure 7b and 
7c, the Matrigel plugs mixed with lal−/− Ly6G+ cells showed larger size and more Ki67 
positive proliferative cells than those mixed with lal+/+ Ly6G+ cells. Furthermore, lal−/− 
Ly6G+ cells with mTOR knockdown significantly reduced their abilities to stimulate cancer 
cell proliferation in in vitro co-culture experiment (Figure 7d). Therefore, lal−/− Ly6G+ cells 
stimulate proliferation of multiple cancer cell models.
Discussion
LAL is a key enzyme in the metabolic pathway of neutral lipids. Based on extensive 
characterization, LAL has a tight connection with inflammation, and its deficiency results in 
multiple pathogenic phenotypes 2, 3, 7, 23, 24. Strikingly, this report discovered that LAL 
deficiency-induced inflammation alleviated the immune rejection by allowing melanoma 
growth (Figure 1a and b) and metastasis to multiple organs in the allogeneic lal−/− mouse 
model (Figure 1c), suggesting that LAL is a critical lipid metabolic enzyme in tumor 
immunology. Understanding the cellular and molecular mechanisms underlying this 
observation will help identify potential targets for antitumor therapies.
The occurrence of metastasis requires cancer cells to survive in the circulation, arrive at the 
target organs, and show persistent proliferation and growth 25. Such multistep process is 
inefficient in the allogeneic mouse model due to immune rejection. However, metastasis can 
be facilitated by the inflammatory environment, especially by interacting with inflammatory 
cells 1. Since hLAL expression in lal−/− myeloid cells partially restored immune rejection of 
B16 melanoma cell in the allogeneic mice model (Figure 1e and f), the myeloid 
compartment must be crucial in controlling cancer cell growth and metastasis. One major 
manifestation during LAL deficiency is systemic MDSC expansion and dysfunction in 
multiple organs of the mice 2, 3, 23, 26, 27, which arises from dysregulated production of 
myeloid progenitor cells in the bone marrow 2. In lal−/− mice, most MDSCs are Ly6G and 
Ly6C double positive, which showed strong suppression on T cell proliferation and 
function 3, similar to those observed in tumor-bearing mice 14, 28, 29. Since B16 melanoma 
cells metastasized massively in the allogeneic lal−/− mouse model, other unidentified 
functions of lal−/− MDSCs have been further explored in addition to their well-known 
immunosuppressive function.
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Indeed, when bone marrow-derived lal−/− MDSCs were co-cultured with B16 melanoma 
cells in vitro, a directly stimulatory effect of lal−/− MDSCs on cancer cell proliferation was 
observed (Figure 2a). This process was partially mediated by several inflammatory 
cytokines secreted by lal−/− MDSCs (Figure 2c and d). This was further supported by in vivo 
Matrigel assay when lal−/− MDSCs and B16 melanoma cells were co-injected into 
allogeneic recipient lal+/+ mice, which showed more robust cancer cell growth in vivo 
(Figure 2b). To our knowledge, this is the first study demonstrating that MDSCs are able to 
directly stimulate cancer cell proliferation both in vitro and in vivo. Importantly, 
proliferation of other cancer cell lines (LLC and Tramp-C2) was also directly stimulated by 
lal−/− MDSCs in vitro and in vivo (Figure 7a–c). Therefore, MDSCs not only possess 
immunosuppressive function to clear a way for cancer growth and progression, but also 
stimulate cancer cell proliferation directly. In these processes, LAL in myeloid cells is 
critically involved in controlling the immunosuppressive function and cancer cell 
proliferation-stimulating function, because MDSCs isolated from hLAL myeloid 
specifically-expressed lal−/− mice showed reduced ability to suppress T cell proliferation 
and function 3, and impaired stimulation on cancer cell proliferation (Figure 2a and b). 
Moreover, after intravenous co-injection of B16 melanoma cells and lal−/− MDSCs into 
allogeneic recipient lal+/+ mice, more melanoma developed in the lungs (Figure 3a–c). 
Therefore, there are at least two cellular mechanisms for lal−/− MDSCs to facilitate cancer 
cell metastasis: 1) stimulate cancer cell proliferation; and 2) suppress immune surveillance. 
It is import to recognize that MDSCs is not the only factor that contributes to cancer 
proliferation and immune suppression. As demonstrated in Figure 1e and f, restoring LAL 
expression in the myeloid cells partially reduced tumor growth and metastasis. Similarly, 
LAL is not the only factor controlling MDSCs malformation and malfunction. The rescue of 
LAL in myeloid cells of c-fms/hLAL/KO mice only partially corrects the abnormality of 
lal−/− MDSCs 3.
Given the importance of lal−/− MDSCs in cancer cell metastasis, it is important to identify 
the molecular mechanisms that mediate lal−/− MDSCs malfunction, especially their 
stimulation on cancer cell proliferation. Identification of such mechanisms and pathways 
will help find pharmacological intervention in immune therapy for cancer treatment. To 
achieve this goal, the intrinsic molecular defects in lal−/− MDSCs were identified by 
Affymetrix GeneChip microarray analysis. Ingenuity Pathway Analysis of gene transcripts 
revealed up-regulation of multiple genes in the mTOR signaling pathway in lal−/− MDSCs. 
The mTOR-associated cellular defects, including increased reactive oxygen species (ROS) 
production, elevated ATP synthesis, and reduced membrane potential, have been observed 
in lal−/− MDSCs as we reported previously 21. So far, there is no study has been done to 
evaluate whether and how the mTOR pathway in MDSCs influences cancer immunology. In 
the present study, we confirmed that LAL deficiency induced over-activation of the mTOR 
pathway in MDSCs by activating the mTOR downstream genes (Figure 4a). Inhibition of 
mTOR in lal−/− MDSCs by siRNA transfection not only impaired their stimulatory effects 
on cancer cell proliferation in in vitro co-culturing assay (Figure 4b and 7d) and in vivo 
Matrigel assay (Figure 4c and d), but also significantly retarded their ability on B16 
melanoma cell metastasis (Figure 5). Tumor-associated F4/80+ macrophages, CD3+ T cells 
and CD31+ endothelial cells in the B16 melanoma cell-injected Matrigel plugs were also 
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reduced after inhibition of mTOR in lal−/− MDSCs by siRNA transfection (Figure 4d), 
suggesting that over-activation of the mTOR pathway in lal−/− MDSCs is a major molecular 
mechanism underlying their stimulatory effects on cancer cell proliferation and metastasis. 
Furthermore, both mTORC1 and mTORC2 were involved in the lal−/− MDSCs’ stimulatory 
activity on B16 melanoma cell proliferation, growth and metastasis (Figure 6). In addition to 
lal−/− MDSCs, inhibition of mTOR, Raptor and Rictor also showed effects in lal+/+ MDSCs 
(Figure 2, 6 and 7). The mTOR signaling pathway is involved in regulating cell growth, 
proliferation, migration, survival, protein synthesis, and transcription in response to growth 
factors and mitogens. It is conceivable that inhibition of mTOR may also suppress the 
normal functions of mTOR in wild type cells. While it is important to suppress abnormal 
activities of MDSCs during cancer treatment, it is critical to control dosage use for patient 
care in the future. Nevertheless, it is still beneficial to treat cancer patients by eliminating 
MDSCs to decrease tumor growth and metastasis, since the mTOR shows over-activation in 
tumor MDSCs.
Recently, we have shown that inhibition of mTOR in lal−/− mice 1) reduced bone marrow 
myelopoiesis and systemic MDSC expansion; 2) reversed the increased cell proliferation, 
decreased apoptosis, increased ATP synthesis, and increased cell cycling of bone marrow-
derived MDSCs; 3) corrected enhanced lal−/− MDSCs development from lineage negative 
progenitor cells; and 4) reversed the immune suppression on T cell proliferation and 
function that are associated with decreased ROS production, and recovery from impairment 
of mitochondrial membrane potential 19. These results indicate a critical role of LAL-
regulated mTOR signaling in the production and function of lal−/− MDSCs.
In conclusion, neutral lipid metabolism controlled by LAL critically regulates MDSCs 
ability to directly stimulate cancer cell proliferation, metastasis, and immune suppression 
through modulation of the mTOR pathway. The mTOR pathway may be served as a novel 
target to modulate the emergence of MDSCs to reduce the risk of cancer metastasis.
Materials and Methods
Animals and cell lines
lal+/+ and lal−/− mice of the FVBN background were bred in house. c-fms-rtTA/(TetO)7-
CMV-hLAL; lal−/−(Tg/KO) triple mice of the FVBN background is a previously generated 
triple transgenic mouse model with myeloid-specific doxycycline-inducible expression of 
wild-type human LAL (hLAL) in lal−/− mice under the control of the c-fms promoter 3, 7. 
All scientific protocols involving the use of animals have been approved by the Institutional 
Animal Care and Use Committee of Indiana University School of Medicine and followed 
guidelines established by the Panel on Euthanasia of the American Veterinary Medical 
Association. Animals were housed under Institutional Animal Care and Use Committee-
approved conditions in a secured animal facility at Indiana University School of Medicine.
The murine B16 melanoma cell line, Lewis lung carcinoma (LLC) cell line, and transgenic 
mouse prostate cancer (TRAMP-C2) cell line (purchased from ATCC) were cultured in 
DMEM supplemented with 10% FBS (Gibco).
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Isolation of bone marrow-derived MDSCs
MDSCs were isolated as we previously described 6, 21. Briefly, bone marrow cells were 
isolated from the femurs and tibias of mice. Cells were first incubated with biotin-
conjugated anti-Ly6G antibody at 4°C for 15 min. After washed with PBS, cells were then 
incubated with anti-biotin microbeads at 4°C for another 15 min. Subsequently, cells were 
subjected to magnetic bead sorting according to the manufacturer’s instructions (Miltenyi 
Biotec.).
In vitro co-culture of MDSCs and B16 melanoma cells
A pilot study has been performed to determine the best ratio between MDSCs and B16 
melanoma cells. B16 melanoma cells were harvested, resuspended and adjusted to density at 
5×104 cells/mL. Isolated MDSCs were used immediately and the cell density was adjusted 
to 5×106 cells/mL. One hundred microliter of MDSCs and 100 μL of B16 melanoma cells 
were mixed, and seeded into a well of 96-well plates in DMEM supplemented with 10% 
FBS. Seventy-two hours later, unattached MDSCs were removed by washing with PBS, and 
the number of attached B16 melanoma cells was counted. Morphologically, MDSCs are 
much smaller than B16 melanoma cells for exclusion.
In vivo Matrigel plug assay with MDSCs and B16 melanoma cells
This assay was performed according to an established method with minor modifications 30. 
MDSCs and B16 melanoma cells were collected separately. A pilot study has been 
performed to determine the best ratio between MDSCs and B16 melanoma cells. After 
washed with PBS, 1×106 MDSCs and 1×105 B16 melanoma cells were mixed, centrifuged 
and resuspended in 40 μL PBS and mixed with 500 μL Matrigel Basement Membrane 
Matrix (BD Biosciences) containing 15 units of heparin (Sigma-Aldrich). The cell-Matrigel-
mixture was then injected subcutaneously into the abdomen of 3-month old lal+/+ mice. 
After 10 days, the mice were sacrificed and plugs were harvested from underneath the skin.
Mouse metastasis models
Four-month old lal+/+ or lal−/− mice were inoculated with 1×105 B16 melanoma cells 
subcutaneously into the flank region and tumor size (length×width2×π/6) was monitored 
every week for 3 weeks. For intravenous injection of B16 melanoma cells, 5×105 B16 
melanoma cells in 200 μL PBS were injected into 4-month old lal+/+ or lal−/− mice via tail 
vein. A pilot study has been performed to determine the best ratio between MDSCs and B16 
melanoma cells. For co-injection of MDSCs and B16 melanoma cells via tail vein, 2×106 
MDSCs and 5×105 B16 melanoma cells were mixed and incubated at 37°C, 5% CO2 for 30 
min. After the incubation, cells were centrifuged, resuspended, and injected intravenously 
into 4-month old recipient lal+/+ mice. Two weeks after the injection, the mice were 
sacrificed and the lungs were harvested for examination of metastasis.
Histology and immunohistochemical staining
The harvested plugs and lungs were fixed with 4% paraformaldehyde in PBS at 4°C for 
overnight. After fixation and embedding in paraffin, tissue sections were cut to 5 μm thick. 
H&E staining and immunohistochemical staining were performed by the Histological Core 
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Facility, Department of Pathology and Laboratory Medicine, Indiana University. The 
following antibodies were tested: Ki67, CD31, CD3, and F4/80. Tumor area quantitative 
analyses were performed by Metamorph 6.02 (Molecular Devises) on images taken by 
Olympus microscopy image system.
Western blot analysis
Western blot analysis was performed as previously described 31. Briefly, MDSCs were lysed 
in Cell Lytic MT lysis buffer (Sigma) with Protease Inhibitor Cocktail (Invitrogen) and 
phosphatase inhibitor 2 and 3 (Sigma) for 15 min on a shaker. After centrifugation for 20 
min at 12 000×g (4°C), the supernatants were saved and protein concentrations of the 
samples were determined using the Pierce BCA Protein Assay Kit (Thermo Scientific). 
Equal amounts of protein (30 μg) were loaded onto SDS-polyacrylamide gels and blotted 
onto PVDF membranes (BioRad). Western blot analysis was performed using antibodies 
against mTOR, phospho-mTOR, p70S6K, phospho-p70S6K, S6, and phospho-S6 (rabbit 
monoclonal antibodies, 1: 1 000, Cell Signaling). Antibody against β-actin (rabbit 
monoclonal anti-β-actin, 1: 2 000, Cell Signaling) was used as a loading control. For 
detection, the membrane was incubated with anti-rabbit IgG secondary antibodies 
conjugated with horseradish peroxidase (1: 2 000, Cell Signaling). Bands were visualized 
using SuperSignal West Pico Chemiluminescent substrate (ThermoScientific Pierce).
Small interfering RNA transfection
Before transfection, MDSCs were seeded into 96-well plates at a density of 1×106 cells/
well. For small interfering RNA (siRNA)-mediated gene knockdown, 50 nmol/L of mTOR 
siRNA SMARTpool (containing a mixture of several siRNAs targeting mTOR), Raptor 
siRNA, Rictor siRNA or control siRNA (Dharmacon) was transfected into MDSCs with 
DharmaFECT Transfection Reagent I (Dharmacon) according to the manufacturer’s 
protocol. After 24 h of transfection, cells were harvested for further analysis.
Real-time RT-PCR
Total RNAs from Ly6G+ cells were purified using the Qiagen total RNA purification kit 
(Qiagen). Quantitative (q)RT-PCR was performed as described previously 6. Analysis was 
performed by the 2−ΔΔCT method. Primers of mIL-6, mIL-1β, mTNF-α and GAPDH for 
real-time PCR were described previously 6.
Transwell assay
For transwell experiment, 0.4-μm pore 6.5-mm diameter transwells were used to separate 
Ly6G+ cells and B16 melanoma cells (Corning) to observe the effect of Ly6G+ cell-secreted 
cytokines on melanoma cell proliferation. Freshly isolated 2×106 Ly6G+ cells in 200 μL 
media were seeded into the upper chamber of transwells, while 2×104 melanoma cells in 
600 μL media were placed in the lower chamber. For the neutralization study, Ly6G+ cells 
were treated with 10 μg/mL neutralizing antibody against IL-6, IL-1β, TNF-α or control 
IgG. After 72 hours’ culture, the transwells were removed, and the number of B16 
melanoma cells in the lower chamber was counted.
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Statistics
Data were expressed as mean ± SD. Differences between two treatment groups were 
compared by Student’s t-test. When more than two groups were compared, one-way 
ANOVA with post-hoc Newman-Keul’s multiple comparison test was used. Results were 
considered statistically significant when P < 0.05. All analyses were performed with 
GraphPad Prism 5.0 (GraphPad).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. B16 melanoma cell growth and metastasis in lal−/− mice
(A) B16 melanoma cells (1×105) were subcutaneously injected into lal+/+ or lal−/− mice for 
3 weeks. A representative picture of tumor was shown. (B) Statistical analysis of tumor 
volume (in cubic millimeters). Data were expressed as mean ± SD; n = 10. ***P<0.0001 at 
week 2 and 3. (C) B16 melanoma cells (5× 105) was intravenously injected into lal+/+ or 
lal−/− mice for 2 weeks. Metastasized B16 melanoma colonies in the lungs and livers are 
shown. (n=10) (D) Representative H&E staining of lung sections and statistical analysis of 
relative tumor areas. Original magnification, ×200. Data were expressed as mean ± SD; n = 
10. ***P<0.0001. (E) Quantitative analysis of B16 melanoma colonies in the lungs of 
doxycycline-treated or untreated Tg/KO triple mice with intravenous injection of 5× 105 
B16 melanoma cells for two week. n = 8~10. *P < 0.05. (F) Statistical analysis of relative 
tumor volume after B16 melanoma cells (1×105) were subcutaneously injected into 
doxycycline-treated or untreated Tg/KO triple mice for 2 weeks. Data were expressed as 
mean ± SD; n = 8. *P<0.05.
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Figure 2. lal−/− Ly6G+ cells directly stimulated B16 melanoma cell proliferation and growth
(A) B16 melanoma cells (5× 103) were co-cultured with Ly6G+ cells (5× 105) from lal+/+ or 
lal−/− mice, or doxycycline-treated or untreated Tg/KO triple mice in vitro for 72 h, and 
numbers of B16 melanoma cells were counted. Data were expressed as mean ± SD; n = 3~4. 
**P < 0.01, *P < 0.05. (B) Matrigel mixed with B16 melanoma cells (1× 105) and Ly6G+ 
cells (1× 106) was implanted subcutaneously into lal+/+ mice for 10 days. Representative 
H&E staining of Matrigel plug sections is shown. Original magnification, ×400. (n=10 for 
Ly6G+ cells from lal+/+ or lal−/− mice, and n=4 for Ly6G+ cells from doxycycline-treated or 
untreated Tg/KO triple mice). (C) Real-time PCR analysis of mRNA expression levels of 
cytokines in lal−/− vs. lal+/+ Ly6G+ cells. The relative gene expression was normalized to 
GAPDH mRNA, and analysis was performed by the 2−ΔΔCT method. Data were expressed 
as means ± SD; n = 4. *P < 0.05. (D) To block cytokines, Ly6G+ cells (2×106) in 200 μL 
media were seeded into the upper chamber of 0.4-μm pore 6.5-mm diameter transwells, 
while B16 melanoma cells (2×104) in 600 μL media were placed in the lower chamber. For 
the neutralization study, Ly6G+ cells were treated with 10 μg/mL neutralizing antibody 
against IL-6, IL-1β, TNF-α individually or in combination, or control IgG. After 72 h, the 
number of B16 melanoma cells was counted. Data were expressed as mean ± SD; n = 4. 
***P < 0.001, **P < 0.01, *P < 0.05.
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Figure 3. lal−/− Ly6G+ cells facilitated B16 melanoma cell migration and metastasis
(A) B16 melanoma cells (5× 105) and Ly6G+ cells (2× 106) from lal+/+ or lal−/− mice were 
intravenously injected into lal+/+ mice for 2 weeks. Representative lungs are shown. n = 10. 
(B) Quantitative analysis of the melanoma colony numbers in the lungs. Data were 
expressed as mean ± SD; n = 8. **P < 0.01. (C) Representative H&E staining and IHC 
staining with Ki67 antibody of the metastasized lungs is shown, including statistical analysis 
of relative tumor areas. Original magnification, ×400. Data were expressed as mean ± SD; n 
= 10. ***P<0.0001.
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Figure 4. mTOR inhibition impaired the ability of lal−/− Ly6G+ cells to enhance B16 melanoma 
cell proliferation and growth
(A) Western blot analysis of the mTOR downstream proteins in lal+/+ or lal−/− Ly6G+ cells. 
Representative blots were shown. (n=4). (B) Ly6G+ cells were transfected with mTOR 
siRNA SMARTpool (containing a mixture of siRNAs targeting mTOR) or control (C) 
siRNA for 24 h, and 5× 105 cells were co-cultured with B16 melanoma cells (5× 103) in 
vitro. The numbers of B16 melanoma cells were counted post 72 h. Data were expressed as 
mean ± SD; n = 5. *P < 0.05, **P < 0.01. (C) Ly6G+ cells (1× 106) after transfection were 
mixed with B16 melanoma cells (1× 105) in Matrigel and implanted subcutaneously into 
lal+/+ mice for 10 days. Representative H&E staining of Matrigel plug sections is shown. 
Original magnification, ×200. (n=10) (D) Representative IHC staining of the Matrigel plug 
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sections using antibodies against Ki67, CD31, F4/80, and CD3. Original magnification, 
×400.
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Figure 5. mTOR inhibition impaired the ability of lal−/− Ly6G+ cells to facilitate B16 melanoma 
cell metastasis
(A) Ly6G+ cells (2× 106) after siRNA transfection were co-injected with B16 melanoma 
cells (5× 105) into lal+/+ mice via tail vein for 2 weeks. Representative lungs were shown. 
(n=5) (B) Representative H&E staining of metastasized lungs and statistical analysis of 
relative tumor areas. Original magnification, ×400. Data were expressed as mean ± SD; n = 
5. ***P<0.001, **P<0.01. (C) Representative IHC staining of metastasized lungs using anti-
Ki67-antibody was shown. Original magnification, ×400.
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Figure 6. Raptor or Rictor inhibition impaired the ability of lal−/− Ly6G+ cells to enhance B16 
melanoma cell proliferation, growth and metastasis
(A) Ly6G+ cells were transfected with Raptor, Rictor siRNA SMARTpool (containing a 
mixture of siRNAs targeting Raptor or Rictor) or control (C) siRNA for 24 h, and then co-
cultured with B16 melanoma cells in vitro. The numbers of B16 melanoma cells were 
counted post 72 h. Data were expressed as mean ± SD; n = 4. *P < 0.05, **P < 0.01. (B) 
Ly6G+ cells after transfection were mixed with B16 melanoma cells in Matrigel and 
implanted subcutaneously into lal+/+ mice for 10 days. Representative H&E staining of 
Matrigel plug sections is shown. Original magnification, ×200. (n=6) (C) Ly6G+ cells after 
transfection were co-injected with B16 melanoma cells intravenously into lal+/+ mice for 2 
weeks. Representative H&E staining of metastasized lungs and statistical analysis of relative 
tumor areas were shown. Original magnification, ×400. Data were expressed as mean ± SD; 
n = 7~8. ***P<0.001.
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Figure 7. lal−/− Ly6G+ cells stimulated LLC and Tramp-C2 growth through over-activation of 
mTOR signaling pathway
(A) LLC cells or Tramp-C2 cells (1× 104) were co-cultured in vitro with lal+/+ or lal−/− 
Ly6G+ cells (5× 105) for 72 h, and the numbers of LLC or Tramp-C2 cells were counted. 
Data were expressed as mean ± SD; n = 4. *P < 0.05, **P < 0.01. (B) LLC or Tramp-C2 
cells (1× 105) and Ly6G+ cells (1× 106) were mixed in Matrigel and implanted 
subcutaneously into lal+/+ mice for 10 days. Representative pictures of Matrigel plugs were 
shown. (n=4) (C) Representative IHC staining with anti-Ki67 antibody of Matrigel plug 
sections was shown. Original magnification, ×400. (D) Ly6G+ cells were transfected with 
mTOR siRNA or control (C) siRNA for 24 h, followed by co-culture with cancer cells in 
vitro. The numbers of LLC or Tramp-C2 cells were counted post 72 h. Data were expressed 
as mean ± SD; n = 4. *P < 0.05, **P < 0.01.
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